HER2 Low Expression in Primary Male Breast Cancer.
Katleen NobbeMelanie Erices-LeclercqFrank FoersterRobert FörsterStephan E BaldusChristian RudlowskiLars SchröderSabine LubigPublished in: Breast cancer (Dove Medical Press) (2024)
Our findings show a notable, albeit lower, prevalence of HER2 low expression in primary MBC. However, tumors expressing HER2 low do not show specific tumor biological features to define a new breast cancer subtype in MBC. Our results suggest that a significant number of MBC patients could benefit from ADCs, as shown in FBC. Further studies are required to better understand HER2 low breast cancer, both generally and in MBC.